Department of Pharmaceutical Sciences, Mercer University College of Pharmacy, Mercer University Health Sciences Center, 3001 Mercer University Dr., Atlanta, GA, 30341, USA.
University of Texas College of Pharmacy, Austin, TX, USA.
Psychopharmacology (Berl). 2019 Dec;236(12):3567-3578. doi: 10.1007/s00213-019-05328-7. Epub 2019 Jul 15.
Approximately 20 million adults in the USA have an alcohol use disorder (AUD). There are clinical and preclinical data suggesting that psychedelics may have benefits for AUD.
To investigate the effects of the synthetic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) on the behavioral effects of ethanol.
The effects of DOI were examined using ethanol-induced place conditioning (1.8 g/kg ethanol) and 2-bottle choice ethanol drinking (20% v/v), using a dose of DOI (3 mg/kg) that produced the maximal response in the serotonin 2A (5-HT) receptor-dependent head-twitch assay. Interactions between DOI and ethanol (3 g/kg) were examined using the ethanol-induced loss of righting reflex procedure and blood-ethanol analysis. To examine additional mechanisms by which psychedelics may interact with ethanol, we determined whether DOI reverses ethanol-induced nitric oxide release in macrophages, a marker of inflammation.
DOI significantly attenuated ethanol-induced place conditioning and ethanol drinking. DOI-induced suppression of alcohol drinking depended upon 5-HT receptors, was selective for alcohol over water, and was selective for high alcohol-preferring subjects. DOI had no apparent pharmacokinetic interactions with ethanol, and DOI reduced ethanol-induced nitric oxide release.
Our findings demonstrate that DOI blocks ethanol place conditioning and selectively reduces voluntary ethanol consumption. This may be related to modulation of the effects of ethanol in the reward circuitry of the brain, ethanol-induced neuroinflammation, or a combination of both. Additional studies to elucidate the mechanisms through which psychedelics attenuate the effects of ethanol would inform the pathophysiology of AUD and potentially provide new treatment options.
美国约有 2000 万成年人患有酒精使用障碍(AUD)。有临床和临床前数据表明,迷幻剂可能对 AUD 有益。
研究合成迷幻剂 2,5-二甲氧基-4-碘苯丙胺(DOI)对乙醇行为效应的影响。
使用 DOI(3mg/kg)剂量,该剂量在 5-羟色胺 2A(5-HT)受体依赖性摇头反应中产生最大反应,使用乙醇诱导的位置条件(1.8g/kg 乙醇)和 2 瓶选择乙醇饮用(20%v/v)来检查 DOI 的作用。DOI 与乙醇(3g/kg)之间的相互作用通过乙醇诱导的翻正反射丧失程序和血液乙醇分析来检查。为了研究迷幻剂与乙醇相互作用的其他机制,我们确定了 DOI 是否逆转了乙醇诱导的巨噬细胞中一氧化氮释放,这是炎症的标志物。
DOI 显著减弱了乙醇诱导的位置条件和乙醇饮用。DOI 诱导的对酒精饮用的抑制作用取决于 5-HT 受体,对酒精有选择性,对高酒精偏好者有选择性。DOI 与乙醇之间没有明显的药代动力学相互作用,并且 DOI 降低了乙醇诱导的一氧化氮释放。
我们的发现表明 DOI 阻断了乙醇位置条件和选择性地减少了自愿性乙醇消耗。这可能与大脑奖励回路中乙醇作用的调制、乙醇诱导的神经炎症或两者的组合有关。进一步阐明迷幻剂减轻乙醇作用的机制的研究将为 AUD 的发病机制提供信息,并可能提供新的治疗选择。